Target Price | $143.34 |
Price | $102.34 |
Potential |
40.06%
register free of charge
|
Number of Estimates | 20 |
20 Analysts have issued a price target BioNTech SE - ADR 2026 .
The average BioNTech SE - ADR target price is $143.34.
This is
40.06%
register free of charge
$178.68
74.59%
register free of charge
$109.27
6.77%
register free of charge
|
|
A rating was issued by 23 analysts: 17 Analysts recommend BioNTech SE - ADR to buy, 6 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the BioNTech SE - ADR stock has an average upside potential 2026 of
40.06%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 2.98 | 2.34 |
27.92% | 21.42% | |
EBITDA Margin | -12.56% | -74.07% |
144.03% | 489.96% | |
Net Margin | -24.11% | -51.12% |
199.24% | 112.02% |
18 Analysts have issued a sales forecast BioNTech SE - ADR 2025 . The average BioNTech SE - ADR sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an BioNTech SE - ADR EBITDA forecast 2025. The average BioNTech SE - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 BioNTech SE - ADR Analysts have issued a net profit forecast 2025. The average BioNTech SE - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.99 | -4.98 |
171.53% | 66.56% | |
P/E | negative | |
EV/Sales | 3.39 |
10 Analysts have issued a BioNTech SE - ADR forecast for earnings per share. The average BioNTech SE - ADR EPS is
This results in the following potential growth metrics and future valuations:
BioNTech SE - ADR...
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
Citigroup |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
BMO Capital |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
Canaccord Genuity |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
Morgan Stanley |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
Truist Securities |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
Wells Fargo |
Locked
➜
Locked
|
Locked | Dec 11 2024 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 01 2025 |
Locked
Citigroup:
Locked
➜
Locked
|
Mar 13 2025 |
Locked
BMO Capital:
Locked
➜
Locked
|
Mar 11 2025 |
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Mar 11 2025 |
Locked
Morgan Stanley:
Locked
➜
Locked
|
Mar 11 2025 |
Locked
Truist Securities:
Locked
➜
Locked
|
Jan 10 2025 |
Locked
Wells Fargo:
Locked
➜
Locked
|
Dec 11 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.